[EN] 1,4-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND THEIR USE FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS<br/>[FR] DÉRIVÉS DE PYRIDAZINE 1,4-DISUBSTITUÉS ET LEUR UTILISATION POUR LE TRAITEMENT DE PATHOLOGIES LIÉES À UNE DÉFICIENCE EN SMN
申请人:NOVARTIS AG
公开号:WO2015017589A1
公开(公告)日:2015-02-05
The present invention provides a compound of formula IA or a pharmaceutically acceptable salt thereof; 5 (IA) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
A series of 5-hydroxyquinolines has been prepared via the Skraup reaction. Several regioisomers were made either by selective displacement of a leaving group or by using a bromo substituent as a blocking group. The bromo group was found to be an excellent blocking group due to its stability during the Skraup reaction and easy removal thereafter. Halides at the 5-position of quinoline were found to
Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions
申请人:Axford Jake
公开号:US09040712B2
公开(公告)日:2015-05-26
The present invention provides a compound of Formula (X) or a pharmaceutically acceptable salt thereof;
a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
1,4-DISUBSTITUTED PYRIDAZINE QUINOLNE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS
申请人:CHEUNG Atwood
公开号:US20160184305A1
公开(公告)日:2016-06-30
The present invention provides a compound of formula IA or a pharmaceutically acceptable salt thereof; 5 (IA) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
THIADIAZOLE ANALOGS AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH A DEFICIENCY OF SMN MOTOR NEURONS
申请人:Novartis AG
公开号:EP3736271A1
公开(公告)日:2020-11-11
The present invention provides a compound of Formula (X) or a pharmaceutically acceptable salt thereof;
a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.